Find ECT Clinical Trials in New York, New York – 218 Enrolling Now

Showing 1–20 of 218 trials

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more

National Cancer Institute (NCI)2,900 enrolled479 locationsNCT05564377

Recruiting

Phase 1

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

Breast NeoplasmsCholangiocarcinomaOvarian Neoplasms+4 more

Eli Lilly and Company241 enrolled28 locationsNCT07213791

Recruiting

Phase 1

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

Breast NeoplasmsColorectal NeoplasmsProstate Neoplasm+2 more

Eli Lilly and Company421 enrolled28 locationsNCT07114601

Recruiting

Phase 1Phase 2

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

Metastatic Breast CancerLocally Advanced Breast CancerUnresectable Breast Carcinoma

BioNTech SE380 enrolled39 locationsNCT06827236

Recruiting

Phase 1

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Breast CancerOvarian CancerColorectal Carcinoma+4 more

AstraZeneca45 enrolled18 locationsNCT05877599

Recruiting

Phase 1

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+37 more

National Cancer Institute (NCI)51 enrolled23 locationsNCT04704661

Recruiting

Phase 1

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+2 more

National Cancer Institute (NCI)57 enrolled6 locationsNCT05422794

Recruiting

Phase 1Phase 2

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

Cervical CancerGastric/Gastroesophageal Junction AdenocarcinomaMicrosatellite Stable Colorectal Cancer

Bristol-Myers Squibb949 enrolled48 locationsNCT04895709

Recruiting

Phase 1

A Phase 1/1b Study of IAM1363 in HER2 Cancers

HER2-positive Breast CancerHER2 + Breast CancerHER2 Mutation-Related Tumors+10 more

Iambic Therapeutics, Inc383 enrolled48 locationsNCT06253871

Recruiting

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Head and Neck CarcinomaMalignant Solid NeoplasmSarcoma+59 more

Alliance for Clinical Trials in Oncology2,000 enrolled745 locationsNCT05334069

Recruiting

National Cancer Institute "Cancer Moonshot Biobank"

Ovarian CarcinomaEsophageal CarcinomaGastric Carcinoma+26 more

National Cancer Institute (NCI)1,600 enrolled152 locationsNCT04314401

Recruiting

Clinical Validation of Early Detection Blood Test for Universal Large-scale Breast Cancer Screening

Breast Cancer, Liquid Biopsy, Early Detection

Syantra Inc.2,000 enrolled4 locationsNCT07219277

Recruiting

Phase 1

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

Breast CancerOvarian CancerProstate Cancer+8 more

Clasp Therapeutics, Inc.90 enrolled21 locationsNCT06778863

Recruiting

Phase 2

A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors

Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal CancerPart 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer

AstraZeneca468 enrolled123 locationsNCT04482309

Recruiting

Phase 1

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+4 more

Relay Therapeutics, Inc.930 enrolled37 locationsNCT05216432

Recruiting

Prospective Study of Sensation and Satisfaction in Cancer and Transgender Mastectomy Patients

Pain, ChronicPain, PostoperativeSensation Disorders+6 more

Weill Medical College of Cornell University400 enrolled2 locationsNCT06094257

Recruiting

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Advanced Solid TumorMetastatic Solid TumorSoft Tissue Sarcoma (STS)+3 more

GI Innovation, Inc.358 enrolled11 locationsNCT05824975

ECT Clinical Trials in New York, New York

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

National Cancer Institute "Cancer Moonshot Biobank"

Clinical Validation of Early Detection Blood Test for Universal Large-scale Breast Cancer Screening

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

Prospective Study of Sensation and Satisfaction in Cancer and Transgender Mastectomy Patients

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

A Study on Pain After Breast Reconstruction

Brodalumab in the Treatment of Immune-Related Adverse Events

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)